biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by rustycaton Oct 05, 2018 9:37am

124 Views

Post# 28751025

RE:In the eyes of the shareholder.....

roadking,
It is just a six-month contract for $90K US. Guess we'll see if such a short duration does anything for BTI's visibility. But, no matter, if BTI still can't put out any positive NRs, Stern can't convince new investors to come in, however, since Day's efforts in direct marketing haven't swayed the needle for the Canadian or US investor, so, perhaps Stern will get some new eyes on BTI.

Bullboard Posts

Southern Ontario mineral processing operation receives green fund support